Cargando…
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer
Breast cancer is one of the most common cancers and the second leading cause of cancer death in the United States. Estrogen receptor (ER)-positive cancer is the most frequent subtype representing more than 70% of breast cancers. These tumors respond to endocrine therapy targeting the ER pathway incl...
Autor principal: | Abdel-Hafiz, Hany A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622332/ https://www.ncbi.nlm.nih.gov/pubmed/28933369 http://dx.doi.org/10.3390/diseases5030016 |
Ejemplares similares
-
Molecular mechanisms and mode of tamoxifen resistance in breast cancer
por: Ali, Shazia, et al.
Publicado: (2016) -
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2019) -
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
por: Ye, Liping, et al.
Publicado: (2022) -
The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer
por: Azzam, Hany N., et al.
Publicado: (2023) -
Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease
por: Knox, Aaron J, et al.
Publicado: (2014)